CN109641041A - 流感病毒血细胞凝集素蛋白及其用途 - Google Patents
流感病毒血细胞凝集素蛋白及其用途 Download PDFInfo
- Publication number
- CN109641041A CN109641041A CN201780049845.1A CN201780049845A CN109641041A CN 109641041 A CN109641041 A CN 109641041A CN 201780049845 A CN201780049845 A CN 201780049845A CN 109641041 A CN109641041 A CN 109641041A
- Authority
- CN
- China
- Prior art keywords
- amino acid
- influenza
- virus
- seq
- chimeric
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000712461 unidentified influenza virus Species 0.000 title claims abstract description 207
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 414
- 229920001184 polypeptide Polymers 0.000 claims abstract description 399
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 399
- 101710154606 Hemagglutinin Proteins 0.000 claims abstract description 347
- 101710093908 Outer capsid protein VP4 Proteins 0.000 claims abstract description 347
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 claims abstract description 347
- 101710176177 Protein A56 Proteins 0.000 claims abstract description 347
- 239000000185 hemagglutinin Substances 0.000 claims abstract description 346
- 238000000034 method Methods 0.000 claims abstract description 77
- 230000028993 immune response Effects 0.000 claims abstract description 25
- 230000001939 inductive effect Effects 0.000 claims abstract description 17
- 125000000539 amino acid group Chemical group 0.000 claims description 1280
- 241000713196 Influenza B virus Species 0.000 claims description 1027
- 241000712431 Influenza A virus Species 0.000 claims description 453
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 374
- 150000001413 amino acids Chemical class 0.000 claims description 252
- 238000006467 substitution reaction Methods 0.000 claims description 251
- 235000006576 Althaea officinalis Nutrition 0.000 claims description 133
- 239000000203 mixture Substances 0.000 claims description 111
- 150000007523 nucleic acids Chemical group 0.000 claims description 106
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 96
- 241000700605 Viruses Species 0.000 claims description 86
- 241001293113 Anas clypeata Species 0.000 claims description 83
- 239000002253 acid Substances 0.000 claims description 83
- 230000002163 immunogen Effects 0.000 claims description 77
- 239000002773 nucleotide Substances 0.000 claims description 76
- 125000003729 nucleotide group Chemical group 0.000 claims description 76
- 102000039446 nucleic acids Human genes 0.000 claims description 75
- 108020004707 nucleic acids Proteins 0.000 claims description 75
- 208000037798 influenza B Diseases 0.000 claims description 60
- 241001168968 Chroicocephalus ridibundus Species 0.000 claims description 56
- 208000037797 influenza A Diseases 0.000 claims description 54
- 210000005220 cytoplasmic tail Anatomy 0.000 claims description 50
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 34
- 229960005486 vaccine Drugs 0.000 claims description 16
- 230000000295 complement effect Effects 0.000 claims description 11
- 229940031626 subunit vaccine Drugs 0.000 claims description 6
- 239000002671 adjuvant Substances 0.000 claims description 5
- 239000002245 particle Substances 0.000 claims description 5
- 230000002238 attenuated effect Effects 0.000 claims description 2
- 108091026890 Coding region Proteins 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 239000002299 complementary DNA Substances 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 239000013603 viral vector Substances 0.000 claims 1
- 230000005875 antibody response Effects 0.000 abstract description 11
- 235000001014 amino acid Nutrition 0.000 description 434
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 109
- 210000003128 head Anatomy 0.000 description 78
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 71
- 229910021529 ammonia Inorganic materials 0.000 description 55
- 241001500350 Influenzavirus B Species 0.000 description 54
- 206010022000 influenza Diseases 0.000 description 47
- 108091092724 Noncoding DNA Proteins 0.000 description 45
- 201000010099 disease Diseases 0.000 description 29
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 28
- 230000003612 virological effect Effects 0.000 description 26
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 24
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 23
- 235000013922 glutamic acid Nutrition 0.000 description 23
- 239000004220 glutamic acid Substances 0.000 description 23
- 210000004027 cell Anatomy 0.000 description 17
- 239000002574 poison Substances 0.000 description 16
- 239000000427 antigen Substances 0.000 description 14
- 108091007433 antigens Proteins 0.000 description 14
- 102000036639 antigens Human genes 0.000 description 14
- 241001500351 Influenzavirus A Species 0.000 description 12
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 12
- 102100029938 Serine/threonine-protein kinase SMG1 Human genes 0.000 description 12
- 231100000614 poison Toxicity 0.000 description 12
- 239000004471 Glycine Substances 0.000 description 11
- 239000004472 Lysine Substances 0.000 description 11
- 230000000890 antigenic effect Effects 0.000 description 10
- 208000015181 infectious disease Diseases 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 8
- 238000004422 calculation algorithm Methods 0.000 description 8
- 230000001086 cytosolic effect Effects 0.000 description 8
- 210000001161 mammalian embryo Anatomy 0.000 description 8
- 235000013601 eggs Nutrition 0.000 description 7
- 238000011081 inoculation Methods 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 238000011282 treatment Methods 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 5
- 230000008859 change Effects 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 238000002649 immunization Methods 0.000 description 4
- 230000003053 immunization Effects 0.000 description 4
- 210000002845 virion Anatomy 0.000 description 4
- 241000272168 Laridae Species 0.000 description 3
- 210000000805 cytoplasm Anatomy 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- 101710186708 Agglutinin Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 101710146024 Horcolin Proteins 0.000 description 2
- 101710189395 Lectin Proteins 0.000 description 2
- 101710179758 Mannose-specific lectin Proteins 0.000 description 2
- 101710150763 Mannose-specific lectin 1 Proteins 0.000 description 2
- 101710150745 Mannose-specific lectin 2 Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 108091029480 NONCODE Proteins 0.000 description 2
- 241000712464 Orthomyxoviridae Species 0.000 description 2
- 241000282898 Sus scrofa Species 0.000 description 2
- 239000000910 agglutinin Substances 0.000 description 2
- 206010064097 avian influenza Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 238000002050 diffraction method Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000010230 functional analysis Methods 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 241000271566 Aves Species 0.000 description 1
- 241000283153 Cetacea Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 208000002979 Influenza in Birds Diseases 0.000 description 1
- 241001504654 Mustela nivalis Species 0.000 description 1
- 206010053159 Organ failure Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241000282373 Panthera pardus Species 0.000 description 1
- 241000282376 Panthera tigris Species 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000725643 Respiratory syncytial virus Species 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- -1 amino Amino Chemical group 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 210000000991 chicken egg Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 244000309457 enveloped RNA virus Species 0.000 description 1
- 244000052637 human pathogen Species 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 208000037799 influenza C Diseases 0.000 description 1
- 229960003971 influenza vaccine Drugs 0.000 description 1
- 108700010900 influenza virus proteins Proteins 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000013520 translational research Methods 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 210000000605 viral structure Anatomy 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16171—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16271—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Pulmonology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662350701P | 2016-06-15 | 2016-06-15 | |
| US62/350,701 | 2016-06-15 | ||
| US201662355679P | 2016-06-28 | 2016-06-28 | |
| US62/355,679 | 2016-06-28 | ||
| PCT/US2017/037384 WO2017218624A1 (en) | 2016-06-15 | 2017-06-14 | Influenza virus hemagglutinin proteins and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109641041A true CN109641041A (zh) | 2019-04-16 |
Family
ID=60663783
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201780049845.1A Pending CN109641041A (zh) | 2016-06-15 | 2017-06-14 | 流感病毒血细胞凝集素蛋白及其用途 |
Country Status (8)
| Country | Link |
|---|---|
| US (4) | US11266734B2 (enExample) |
| EP (1) | EP3471767A4 (enExample) |
| JP (2) | JP7237344B2 (enExample) |
| CN (1) | CN109641041A (enExample) |
| BR (1) | BR112018075032A2 (enExample) |
| CA (1) | CA3023143A1 (enExample) |
| MX (1) | MX2018015755A (enExample) |
| WO (1) | WO2017218624A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2012011300A (es) | 2010-03-30 | 2012-11-29 | Sinai School Medicine | Vacunas del virus de influenza y usos de las mismas. |
| AU2012312529B2 (en) | 2011-09-20 | 2018-01-04 | Icahn School Of Medicine At Mount Sinai | Influenza virus vaccines and uses thereof |
| CN105263516A (zh) | 2012-12-18 | 2016-01-20 | 西奈山伊坎医学院 | 流感病毒疫苗及其用途 |
| US9908930B2 (en) | 2013-03-14 | 2018-03-06 | Icahn School Of Medicine At Mount Sinai | Antibodies against influenza virus hemagglutinin and uses thereof |
| CA2974699A1 (en) | 2015-01-23 | 2016-07-28 | Icahn School Of Medicine At Mount Sinai | Influenza virus vaccination regimens |
| BR112018075032A2 (pt) | 2016-06-15 | 2019-03-26 | Icahn School Of Medicine At Mount Sinai | proteínas de hemaglutinina do vírus influenza e seus uso |
| US11254733B2 (en) | 2017-04-07 | 2022-02-22 | Icahn School Of Medicine At Mount Sinai | Anti-influenza B virus neuraminidase antibodies and uses thereof |
| KR101964044B1 (ko) | 2018-03-14 | 2019-04-02 | 인제대학교 산학협력단 | 재조합 아데노바이러스를 이용한 다가형 인플루엔자 생백신 플랫폼 |
| US12364746B2 (en) | 2018-06-21 | 2025-07-22 | Icahn School Of Medicine At Mount Sinai | Mosaic influenza virus hemagglutinin polypeptides and uses thereof |
| WO2020232426A1 (en) * | 2019-05-16 | 2020-11-19 | Vanderbilt University | Peptide vaccine based on a new universal influenza a hemagglutinin head domain epitope and human monoclonal antibodies binding thereto |
| WO2020264141A1 (en) * | 2019-06-26 | 2020-12-30 | Icahn School Of Medicine At Mount Sinai | Influenza virus neuraminidase and uses thereof |
| PH12022550963A1 (en) * | 2019-10-28 | 2023-09-25 | Regeneron Pharma | Anti-hemagglutinin antibodies and methods of use thereof |
| JP2025515966A (ja) * | 2022-05-31 | 2025-05-20 | ＶＬＰ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｊａｐａｎ株式会社 | 改変ワクチン設計の開発 |
| CN116284432A (zh) * | 2022-09-09 | 2023-06-23 | 中山大学·深圳 | 一种乙型流感病毒重组蛋白疫苗及其制备方法 |
| WO2025072921A1 (en) * | 2023-09-29 | 2025-04-03 | Icahn School Of Medicine At Mount Sinai | Chimeric influenza virus hemagglutinin mrna-based vaccines and uses thereof |
| WO2025184346A1 (en) * | 2024-02-29 | 2025-09-04 | Icahn School Of Medicine At Mount Sinai | Immunogenic compositions containing inactivated influenza b virus and cpg oligonucleotide adjuvant and uses thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104185476A (zh) * | 2011-09-20 | 2014-12-03 | 西奈山医学院 | 流感病毒疫苗及其应用 |
| CN105263516A (zh) * | 2012-12-18 | 2016-01-20 | 西奈山伊坎医学院 | 流感病毒疫苗及其用途 |
Family Cites Families (212)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4444887A (en) | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
| US4722848A (en) | 1982-12-08 | 1988-02-02 | Health Research, Incorporated | Method for immunizing animals with synthetically modified vaccinia virus |
| US5174993A (en) | 1981-12-24 | 1992-12-29 | Health Research Inc. | Recombinant avipox virus and immunological use thereof |
| US4769330A (en) | 1981-12-24 | 1988-09-06 | Health Research, Incorporated | Modified vaccinia virus and methods for making and using the same |
| US4603112A (en) | 1981-12-24 | 1986-07-29 | Health Research, Incorporated | Modified vaccinia virus |
| US5833975A (en) | 1989-03-08 | 1998-11-10 | Virogenetics Corporation | Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence |
| US5110587A (en) | 1981-12-24 | 1992-05-05 | Health Research, Incorporated | Immunogenic composition comprising synthetically modified vaccinia virus |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4716111A (en) | 1982-08-11 | 1987-12-29 | Trustees Of Boston University | Process for producing human antibodies |
| ZA836080B (en) | 1982-08-23 | 1984-04-25 | Scripps Clinic Res | Broad spectrum influenza antisera |
| US4693981A (en) | 1983-12-20 | 1987-09-15 | Advanced Genetics Research Institute | Preparation of inactivated viral vaccines |
| US5106619A (en) | 1983-12-20 | 1992-04-21 | Diamond Scientific Co. | Preparation of inactivated viral vaccines |
| US5182192A (en) | 1987-03-27 | 1993-01-26 | The Wistar Institute | Monoclonal antibodies against glycolipid antigens, methods of producing these antibodies, and use therefor |
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| US5413923A (en) | 1989-07-25 | 1995-05-09 | Cell Genesys, Inc. | Homologous recombination for universal donor cells and chimeric mammalian hosts |
| US5166057A (en) | 1989-08-28 | 1992-11-24 | The Mount Sinai School Of Medicine Of The City University Of New York | Recombinant negative strand rna virus expression-systems |
| US6001634A (en) | 1989-08-28 | 1999-12-14 | Palese; Peter | Recombinant negative strand RNA viruses |
| US5854037A (en) | 1989-08-28 | 1998-12-29 | The Mount Sinai School Of Medicine Of The City University Of New York | Recombinant negative strand RNA virus expression systems and vaccines |
| US20060019350A1 (en) | 1989-08-28 | 2006-01-26 | Peter Palese | Recombinant negative strand RNA virus expression system and vacccines |
| EP1690935A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US6887699B1 (en) | 1990-05-22 | 2005-05-03 | Medimmune Vaccines, Inc. | Recombinant negative strand RNA virus expression systems and vaccines |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| FR2664905B1 (fr) | 1990-07-18 | 1994-08-12 | Agronomique Inst Nat Rech | Baculovirus modifie, son procede d'obtention, et vecteurs d'expression obtenus a partir dudit baculovirus. |
| JP2938569B2 (ja) | 1990-08-29 | 1999-08-23 | ジェンファーム インターナショナル，インコーポレイティド | 異種免疫グロブリンを作る方法及びトランスジェニックマウス |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5484719A (en) | 1991-08-26 | 1996-01-16 | Edible Vaccines, Inc. | Vaccines produced and administered through edible plants |
| US5612487A (en) | 1991-08-26 | 1997-03-18 | Edible Vaccines, Inc. | Anti-viral vaccines expressed in plants |
| US6034298A (en) | 1991-08-26 | 2000-03-07 | Prodigene, Inc. | Vaccines expressed in plants |
| WO1993011236A1 (en) | 1991-12-02 | 1993-06-10 | Medical Research Council | Production of anti-self antibodies from antibody segment repertoires and displayed on phage |
| US6022726A (en) | 1992-02-03 | 2000-02-08 | Palese; Peter | Genetically engineered attenuated viruses |
| JP3037554B2 (ja) | 1993-04-20 | 2000-04-24 | 寳酒造株式会社 | 免疫原性人工ポリペプチド |
| US6337070B1 (en) | 1993-04-29 | 2002-01-08 | Takara Shuzo Co., Ltd. | Polypeptides for use in generating anti-human influenza virus antibodies |
| US5589174A (en) | 1992-09-17 | 1996-12-31 | Takara Shuzo Co., Ltd. | Anti-human influenza virus antibody |
| EP0621339B1 (en) | 1992-09-17 | 2001-10-24 | Takara Shuzo Co. Ltd. | Immunogenic human influenza A virus haemagglutinin polypeptides |
| GB9221654D0 (en) | 1992-10-15 | 1992-11-25 | Scotgen Ltd | Recombinant human anti-cytomegalovirus antibodies |
| WO1994012629A1 (en) | 1992-12-02 | 1994-06-09 | Baylor College Of Medicine | Episomal vectors for gene therapy |
| WO1994016109A1 (en) | 1993-01-15 | 1994-07-21 | Whitehead Institute For Biomedical Research | Membrane fusion events and means for altering same |
| WO1994017826A1 (en) | 1993-02-01 | 1994-08-18 | Smithkline Beecham Corporation | Vaccinal polypeptides |
| US5573916A (en) | 1994-05-19 | 1996-11-12 | Coretech, Inc. | Immunogenic constructs comprising b-cell and t-cell epitopes on common carrier |
| US5505947A (en) | 1994-05-27 | 1996-04-09 | The University Of North Carolina At Chapel Hill | Attenuating mutations in Venezuelan Equine Encephalitis virus |
| US5622701A (en) | 1994-06-14 | 1997-04-22 | Protein Design Labs, Inc. | Cross-reacting monoclonal antibodies specific for E- and P-selectin |
| ES2210273T5 (es) | 1994-07-18 | 2010-03-29 | Conzelmann, Karl-Klaus, Prof. Dr. | Virus con arn de cadena negativa no segmentado recombinante infeccioso. |
| EP0789774A2 (en) | 1994-10-03 | 1997-08-20 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Enhanced immune response by introduction of cytokine gene and/or costimulatory molecule b7 gene in a recombinant virus expressing system |
| DE69637481T2 (de) | 1995-04-27 | 2009-04-09 | Amgen Fremont Inc. | Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8 |
| EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
| US7153510B1 (en) | 1995-05-04 | 2006-12-26 | Yale University | Recombinant vesiculoviruses and their uses |
| EP0780475B2 (en) | 1995-08-09 | 2006-07-19 | SCHWEIZ. SERUM- & IMPFINSTITUT BERN | Process for the production of infectious negative-strand RNA viruses |
| DE69637875D1 (de) | 1995-09-14 | 2009-04-30 | Virginia Tech Intell Prop | Produktion von lysosomalen enzymen in pflanzlichen expressionssystemen |
| US6264957B1 (en) | 1995-09-27 | 2001-07-24 | The United States Of America As Represented By The Department Of Health And Human Services | Product of infectious respiratory syncytial virus from cloned nucleotide sequences |
| JP2820106B2 (ja) | 1996-02-29 | 1998-11-05 | 日本電気株式会社 | トラヒックシェーパ装置 |
| WO1997040161A1 (en) | 1996-04-19 | 1997-10-30 | Henry M. Jackson Foundation For The Advancement Of Military Medecine | Histidine-tagged intimin and methods of using intimin to stimulate an immune response and as an antigen carrier with targeting capability |
| US6261561B1 (en) | 1996-04-19 | 2001-07-17 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Method of stimulating an immune response by administration of host organisms that express intimin alone or as a fusion protein with one or more other antigens |
| WO1998002530A1 (en) | 1996-07-15 | 1998-01-22 | The Government Of The United States Of America, As Represented By The Department Of Health And Human Services | Production of attenuated respiratory syncytial virus vaccines from cloned nucleotide sequences |
| IL155588A0 (en) | 2003-04-27 | 2003-11-23 | Metabogal Ltd | Methods for expression of enzymatically active recombinant lysosomal enzymes in transgenic plant root cells and vectors used thereby |
| US20050032211A1 (en) | 1996-09-26 | 2005-02-10 | Metabogal Ltd. | Cell/tissue culturing device, system and method |
| JP2000517194A (ja) | 1996-09-27 | 2000-12-26 | アメリカン・サイアナミド・カンパニー | モノネガビラレス（Ｍｏｎｏｎｅｇａｖｉｒａｌｅｓ）と称される目のウイルスにおける弱毒化の原因となる３’ゲノムプロモーター領域およびポリメラーゼ遺伝子の突然変異 |
| US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
| ES2301183T3 (es) | 1996-12-03 | 2008-06-16 | Amgen Fremont Inc. | Anticuerpo completamente humano que se une al receptor del egfr. |
| US5891705A (en) | 1997-04-08 | 1999-04-06 | Pentose Pharmaceuticals, Inc. | Method for inactivating a virus |
| CN100387621C (zh) | 1997-04-14 | 2008-05-14 | 麦可麦脱股份公司 | 抗人抗原受体的新的生产方法及其用途 |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| CN1250725C (zh) | 1997-05-23 | 2006-04-12 | 美国政府健康及人类服务部 | 从克隆的核苷酸序列制备减毒副流感病毒疫苗的方法 |
| US6165476A (en) | 1997-07-10 | 2000-12-26 | Beth Israel Deaconess Medical Center | Fusion proteins with an immunoglobulin hinge region linker |
| DE69837764T2 (de) | 1997-07-11 | 2008-01-31 | Yale University, New Haven | Rhabdovirus mit gentechnisch veränderter hülle |
| CA2302867A1 (en) | 1997-09-19 | 1999-04-01 | American Cyanamid Company | Attenuated respiratory syncytial viruses |
| CA2334857C (en) | 1998-06-12 | 2012-03-20 | Mount Sinai School Of Medicine Of The City University Of New York | Interferon inducing genetically engineered attenuated viruses |
| WO1999064570A1 (en) | 1998-06-12 | 1999-12-16 | Mount Sinai School Of Medicine Of The City University Of New York | Novel methods and interferon deficient substrates for the propagation of viruses |
| US6544785B1 (en) | 1998-09-14 | 2003-04-08 | Mount Sinai School Of Medicine Of New York University | Helper-free rescue of recombinant negative strand RNA viruses |
| US6146642A (en) | 1998-09-14 | 2000-11-14 | Mount Sinai School Of Medicine, Of The City University Of New York | Recombinant new castle disease virus RNA expression systems and vaccines |
| CA2357004A1 (en) | 1998-12-23 | 2000-06-29 | Boyce Thompson Institute For Plant Research | Expression of immunogenic hepatitis b surface antigens in transgenic plants |
| AT407958B (de) | 1999-02-11 | 2001-07-25 | Immuno Ag | Inaktivierte influenza-virus-vakzine zur nasalen oder oralen applikation |
| US8715940B2 (en) | 1999-04-06 | 2014-05-06 | Wisconsin Alumni Research Foundation | Method of making recombinant influenza virus |
| HUP0300187A3 (en) | 1999-04-29 | 2004-11-29 | Syngenta Ltd Haslemere | Herbicide resistant plants |
| AU5998400A (en) | 1999-07-14 | 2001-01-30 | Mount Sinai School Of Medicine Of The City University Of New York, The | In vitro reconstitution of segmented negative-strand rna viruses |
| WO2001021151A1 (en) | 1999-09-24 | 2001-03-29 | Smithkline Beecham Biologicals S.A. | Intranasal influenza virus vaccine |
| US7521220B2 (en) | 1999-11-26 | 2009-04-21 | Crucell Holland B.V. | Production of vaccines |
| WO2001071014A2 (en) | 2000-03-17 | 2001-09-27 | Boyce Thompson Institute For Plant Research, Inc. | Expression of recombinant human acetylcholinesterase in transgenic plants |
| AU2001259211B2 (en) | 2000-04-28 | 2006-07-13 | St. Jude Children's Research Hospital | DNA transfection system for the generation of infectious influenza virus |
| US6632620B1 (en) | 2000-06-22 | 2003-10-14 | Andrew N. Makarovskiy | Compositions for identification and isolation of stem cells |
| ES2295175T3 (es) | 2000-06-23 | 2008-04-16 | Wyeth Holdings Corporation | Ensamblaje de particulas similares al virus (vlp) de la gripe de tipo salvaje y quimericas. |
| KR100881923B1 (ko) | 2000-12-27 | 2009-02-04 | 다이나박스 테크놀로지 코퍼레이션 | 면역자극 폴리뉴클레오티드 및 그것의 사용 방법 |
| US7132510B2 (en) | 2000-12-29 | 2006-11-07 | Bio-Technology General (Israel) Ltd. | Specific human antibodies for selective cancer therapy |
| JP4430942B2 (ja) | 2002-02-13 | 2010-03-10 | ウィスコンシン・アルムナイ・リサーチ・ファウンデーション | インフルエンザウイルスベクターのパッケージングのためのシグナル |
| US20040091503A1 (en) | 2002-08-20 | 2004-05-13 | Genitrix, Llc | Lectin compositions and methods for modulating an immune response to an antigen |
| WO2004067553A2 (en) | 2003-01-29 | 2004-08-12 | The Research Foundation Of The State University Of New York | Tolerance-induced targeted antibody production |
| ATE426412T1 (de) | 2003-01-30 | 2009-04-15 | Novartis Vaccines & Diagnostic | Adjuvante influenza-vakzine |
| US7695725B2 (en) | 2003-02-06 | 2010-04-13 | Aduro Biotech | Modified free-living microbes, vaccine compositions and methods of use thereof |
| JP4368594B2 (ja) | 2003-02-24 | 2009-11-18 | 株式会社インシリコサイエンス | タンパク質構造予測装置、タンパク質構造予測方法、プログラム、および、記録媒体 |
| US7951557B2 (en) | 2003-04-27 | 2011-05-31 | Protalix Ltd. | Human lysosomal proteins from plant cell culture |
| AU2004235813B2 (en) | 2003-05-05 | 2010-07-29 | Boyce Thompson Institute For Plant Research | Vectors and cells for preparing immunoprotective compositions derived from transgenic plants |
| KR101412271B1 (ko) | 2003-05-09 | 2014-06-25 | 듀크 유니버시티 | Ｃｄ２０-특이적 항체 및 이를 이용한 방법 |
| WO2005018539A2 (en) | 2003-06-16 | 2005-03-03 | Medimmune Vaccines, Inc. | Influenza hemagglutinin and neuraminidase variants |
| US8592197B2 (en) | 2003-07-11 | 2013-11-26 | Novavax, Inc. | Functional influenza virus-like particles (VLPs) |
| US8551756B2 (en) | 2003-07-11 | 2013-10-08 | Novavax, Inc. | Avian influenza chimeric VLPS |
| ES2437858T3 (es) | 2003-11-04 | 2014-01-14 | The Administrators Of The Tulane Educational Fund | Método para impedir la fusión virus:célula inhibiendo la función de la región de inicio de fusión en virus de ARN que tienen proteínas de envoltura fusogénicas de membrana de clase I |
| ES2393492T3 (es) | 2004-05-25 | 2012-12-21 | Medimmune, Llc | Variantes de hemaglutinina y neuraminidasa de influenza |
| ATE468390T1 (de) | 2004-10-13 | 2010-06-15 | Protalix Ltd | System und verfahren zur produktion von antikörpern in der pflanzenzellkultur |
| AU2005337178A1 (en) | 2004-11-19 | 2007-04-19 | Wisconsin Alumni Research Foundation | Recombinant influenza vectors with tandem transcription units |
| US8137676B2 (en) | 2005-02-15 | 2012-03-20 | Mount Sinai School Of Medicine | Genetically engineered equine influenza virus and uses thereof |
| CA2598884A1 (en) | 2005-02-24 | 2006-10-05 | University Of Massachusetts | Influenza nucleic acids, polypeptides, and uses thereof |
| ATE549358T1 (de) | 2005-03-24 | 2012-03-15 | Thrombogenics Nv | Neuer anti-plgf-antikörper |
| EP1885186B1 (en) | 2005-06-01 | 2015-09-02 | California Institute Of Technology | Method of targeted gene delivery using viral vectors |
| JP4758148B2 (ja) | 2005-06-14 | 2011-08-24 | 泰三 宇田 | インフルエンザウイルスのヘマグルチニンに対する抗体酵素 |
| US7951384B2 (en) | 2005-08-05 | 2011-05-31 | University Of Massachusetts | Virus-like particles as vaccines for paramyxovirus |
| NZ568211A (en) | 2005-11-04 | 2011-11-25 | Novartis Vaccines & Diagnostic | Influenza vaccines including combinations of particulate adjuvants and immunopotentiators |
| EP1790664A1 (en) | 2005-11-24 | 2007-05-30 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against claudin-18 for treatment of cancer |
| SG176468A1 (en) | 2005-12-02 | 2011-12-29 | Sinai School Medicine | Chimeric viruses presenting non-native surface proteins and uses thereof |
| ATE552846T1 (de) | 2005-12-06 | 2012-04-15 | Yeda Res & Dev | Verbesserter grippeimpfstoff |
| US10183986B2 (en) | 2005-12-15 | 2019-01-22 | Industrial Technology Research Institute | Trimeric collagen scaffold antibodies |
| BRPI0707733B1 (pt) | 2006-02-13 | 2019-12-31 | Ibio, Inc. | antígeno isolado, composição de vacina, uso da referida composição e método para produção de uma proteína de antígeno |
| US20070207171A1 (en) | 2006-03-01 | 2007-09-06 | Cerus Corporation | Engineered listeria and methods of use thereof |
| ES2555544T3 (es) | 2006-03-07 | 2016-01-04 | Vaxinnate Corporation | Composiciones que incluyen hemaglutinina, métodos de preparación y métodos de uso de las mismas |
| WO2007109812A2 (en) | 2006-03-23 | 2007-09-27 | Novartis Ag | Immunopotentiating compounds |
| ATE539079T1 (de) | 2006-03-23 | 2012-01-15 | Novartis Ag | Imidazochinoxalinverbindungen als immunmodulatoren |
| US20100068223A1 (en) | 2006-03-24 | 2010-03-18 | Hanno Scheffczik | Storage of Influenza Vaccines Without Refrigeration |
| AU2007245192B2 (en) | 2006-03-31 | 2012-04-12 | Wisconsin Alumni Research Foundation | High titer recombinant influenza viruses for vaccines |
| WO2007130330A2 (en) | 2006-05-01 | 2007-11-15 | Technovax, Inc. | Polyvalent influenza virus-like particle (vlp) compositions |
| US20070262178A1 (en) | 2006-05-12 | 2007-11-15 | Ultradent Products, Inc. | Syringe delivery tip including an enlarged flocked wing element adjacent a distal delivery end |
| US20080014205A1 (en) | 2006-05-15 | 2008-01-17 | Lawrence Horowitz | Neutralizing Antibodies to Influenza Viruses |
| US8148085B2 (en) | 2006-05-15 | 2012-04-03 | Sea Lane Biotechnologies, Llc | Donor specific antibody libraries |
| WO2008054540A2 (en) | 2006-05-18 | 2008-05-08 | Pharmexa Inc. | Inducing immune responses to influenza virus using polypeptide and nucleic acid compositions |
| WO2008005777A2 (en) | 2006-06-30 | 2008-01-10 | Novavax, Inc. | Methods of enhancing protein incorporation into virus like particles |
| WO2008011636A2 (en) | 2006-07-21 | 2008-01-24 | California Institute Of Technology | Targeted gene delivery for dendritic cell vaccination |
| EA017203B1 (ru) | 2006-09-07 | 2012-10-30 | Круселл Холланд Б.В. | Связывающие молекулы человека, способные нейтрализовать вирус гриппа h5n1, и их применение |
| CA3016948A1 (en) | 2006-09-11 | 2008-03-20 | Seqirus UK Limited | Making influenza virus vaccines without using eggs |
| CN103254308B (zh) | 2007-06-15 | 2015-01-21 | 厦门大学 | H5亚型禽流感病毒血凝素蛋白的单克隆抗体或其结合活性片段及其用途 |
| EP2014279A1 (en) | 2007-06-22 | 2009-01-14 | Pevion Biotech AG | Virosomes comprising hemagglutinin derived from an influenza virus produced in a cell line, compositions, methods of manufacturing, use thereof |
| EA201070066A1 (ru) | 2007-06-27 | 2010-06-30 | Новартис Аг | Вакцины против гриппа с низким содержанием добавок |
| CA2615372A1 (en) | 2007-07-13 | 2009-01-13 | Marc-Andre D'aoust | Influenza virus-like particles (vlps) comprising hemagglutinin |
| JP5187883B2 (ja) | 2007-07-18 | 2013-04-24 | 独立行政法人科学技術振興機構 | 抗原ペプチドおよびその利用 |
| EP2175883A4 (en) | 2007-07-19 | 2011-11-30 | Novavax Inc | CHIMERIC VARICELLA ZOSTER VIRUS-VIRUSUAL PARTICLES |
| WO2009025770A2 (en) | 2007-08-17 | 2009-02-26 | Wyeth | A heterologous prime-boost immunization regimen |
| WO2009088401A2 (en) | 2007-09-24 | 2009-07-16 | Government Of The Usa, As Represented By The Secretary, Dept. Of Health And Human Services | Immunostimulatory combinations of tlr ligands and methods of use |
| FR2921387B1 (fr) | 2007-09-26 | 2012-04-20 | Sanofi Pasteur | Procede de production du virus de la grippe |
| GB0810305D0 (en) | 2008-06-05 | 2008-07-09 | Novartis Ag | Influenza vaccination |
| CN103122354B (zh) | 2007-11-27 | 2018-03-23 | 麦迪卡格公司 | 表达血凝素之转基因植物中生产的重组流感病毒样颗粒(vlp) |
| EP3524619A1 (en) | 2007-12-06 | 2019-08-14 | Dana-Farber Cancer Institute, Inc. | Antibodies against influenza virus and methods of use thereof |
| WO2009092038A1 (en) | 2008-01-16 | 2009-07-23 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Influenza dna vaccination and methods of use thereof |
| ITTO20080204A1 (it) | 2008-03-17 | 2009-09-18 | Pomona Biotechnologies Llc | Anticorpi monoclonali atti a reagire con una pluralita di sottotipi del virus influenzale a |
| EP2698380A1 (en) | 2008-03-28 | 2014-02-19 | Sea Lane Biotechnologies, LLC | Neutralizing molecules to viral antigens |
| GB0905570D0 (en) | 2009-03-31 | 2009-05-13 | Novartis Ag | Combined vaccines |
| WO2010003766A2 (en) | 2008-06-17 | 2010-01-14 | Apogenix Gmbh | Multimeric tnf receptors |
| EP2300609B1 (en) | 2008-06-25 | 2013-11-20 | INSERM - Institut National de la Santé et de la Recherche Médicale | Novel immunoadjuvant flagellin-based compounds and use thereof |
| ES2545607T3 (es) | 2008-07-08 | 2015-09-14 | Medicago Inc. | Antígenos de la gripe recombinantes solubles |
| EP2344568B1 (en) | 2008-09-23 | 2017-12-20 | Nexam Chemical AB | Acetylenic polyamide |
| WO2010036948A2 (en) | 2008-09-26 | 2010-04-01 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Dna prime/inactivated vaccine boost immunization to influenza virus |
| EP2411049B1 (en) | 2009-03-27 | 2020-01-15 | Academia Sinica | Methods and compositions for immunization against virus |
| EP3009145A1 (en) | 2009-03-30 | 2016-04-20 | Mount Sinai School of Medicine of New York University | Influenza virus vaccines and uses thereof |
| WO2010130636A1 (en) | 2009-05-11 | 2010-11-18 | Crucell Holland B.V. | Human binding molecules capable of neutralizing influenza virus h3n2 and uses thereof |
| JP5941841B2 (ja) | 2009-05-26 | 2016-06-29 | アイカーン スクール オブ メディシン アット マウント サイナイ | 周期的投与によって作製されたインフルエンザウイルスに対するモノクローナル抗体及びその使用 |
| KR101377725B1 (ko) | 2009-06-24 | 2014-03-27 | 메디카고 인코포레이티드 | 헤마글루티닌을 포함하는 키메라 인플루엔자 바이러스-유사 입자 |
| JP5845180B2 (ja) | 2009-07-30 | 2016-01-20 | モウント シナイ スクール オフ メディシネ | インフルエンザウイルス及びそれらの使用 |
| JP5463107B2 (ja) | 2009-09-14 | 2014-04-09 | 独立行政法人国立国際医療研究センター | 新型インフルエンザを特異的に鑑別するモノクローナル抗体とそれを利用した免疫検出試薬 |
| WO2011044152A1 (en) | 2009-10-05 | 2011-04-14 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services Office Of Technology Transfer | Protection against pandemic and seasonal strains of influenza |
| JP2013060367A (ja) | 2010-01-15 | 2013-04-04 | Osaka Univ | 抗インフルエンザ抗体及びインフルエンザ検出用デバイス |
| US20140004149A1 (en) | 2010-01-24 | 2014-01-02 | Biological Mimetics, Inc. | Immunogenic Influenza Composition |
| US8298820B2 (en) | 2010-01-26 | 2012-10-30 | The Trustees Of The University Of Pennsylvania | Influenza nucleic acid molecules and vaccines made therefrom |
| CA2790380A1 (en) | 2010-02-18 | 2011-08-25 | Mount Sinai School Of Medicine | Vaccines for use in the prophylaxis and treatment of influenza virus disease |
| PH12012501751A1 (en) | 2010-03-04 | 2012-11-12 | Macrogenics Inc | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof |
| EP2545074A4 (en) | 2010-03-08 | 2014-01-08 | Celltrion Inc | HUMAN MONOCLONAL ANTIBODIES MADE FROM HUMAN B-CELLS WITH NEUTRALIZING EFFECT AGAINST INFLUENZA A-VIRUS |
| MX2012011300A (es) | 2010-03-30 | 2012-11-29 | Sinai School Medicine | Vacunas del virus de influenza y usos de las mismas. |
| CN102939102A (zh) | 2010-04-09 | 2013-02-20 | 乌得勒支大学控股有限责任公司 | 重组多聚流感蛋白 |
| NZ629829A (en) | 2010-04-30 | 2015-11-27 | Alexion Pharma Inc | Anti-c5a antibodies and methods for using the antibodies |
| AU2011282423B2 (en) | 2010-07-22 | 2015-05-14 | Schrader, Sabariah | Cross-protective pathogen protection, methods and compositions thereof |
| AU2011344126B2 (en) | 2010-12-13 | 2016-11-10 | The University Of Utah Research Foundation | Vaccine antigens that direct immunity to conserved epitopes |
| US8841418B2 (en) | 2011-07-01 | 2014-09-23 | Cellerant Therapeutics, Inc. | Antibodies that specifically bind to TIM3 |
| WO2013079473A1 (en) | 2011-11-28 | 2013-06-06 | Crucell Holland B.V. | Influenza virus vaccines and uses thereof |
| WO2013174403A1 (en) | 2012-05-23 | 2013-11-28 | Ganymed Pharmaceuticals Ag | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer |
| CN103665155B (zh) | 2012-09-14 | 2016-07-06 | 中国科学院上海生命科学研究院 | 一种抗流感病毒广谱中和性的中和分子1f2 |
| KR101452865B1 (ko) | 2012-09-17 | 2014-10-21 | 서울대학교산학협력단 | 신규한 ｉｐ－１０ 에피토프 및 이에 대한 항체 |
| CA2894506C (en) | 2012-12-11 | 2021-08-10 | Vib Vzw | Anti-influenza antibody |
| EP2943221A1 (en) | 2013-01-10 | 2015-11-18 | Novartis AG | Influenza virus immunogenic compositions and uses thereof |
| TR201908761T4 (tr) | 2013-02-22 | 2019-07-22 | Abbvie Stemcentrx Llc | Antidll3-antikor-pbd konjugatları ve kullanımları. |
| EP2968512A2 (en) * | 2013-03-13 | 2016-01-20 | Novartis AG | Influenza b virus reassortment |
| US20140286981A1 (en) | 2013-03-14 | 2014-09-25 | Wisconsin Alumni Research Foundation | Broadly reactive mosaic peptide for influenza vaccine |
| US9908930B2 (en) | 2013-03-14 | 2018-03-06 | Icahn School Of Medicine At Mount Sinai | Antibodies against influenza virus hemagglutinin and uses thereof |
| JP6595448B2 (ja) | 2013-03-14 | 2019-10-23 | コントラフェクト コーポレイション | 治療効率の増強のために鼻腔内送達する中和抗体に基づく組成物および方法 |
| WO2014151747A1 (en) | 2013-03-15 | 2014-09-25 | Ramot At Tel Aviv University Ltd. | Methods and compositions with immune therapy for treatment of dementia |
| WO2014150835A1 (en) | 2013-03-15 | 2014-09-25 | The Trustees Of The University Of Pennsylvania | Influenza nucleic acid molecules and vaccines made therefrom |
| US9850297B2 (en) | 2013-03-15 | 2017-12-26 | Amgen Inc. | Secreted frizzle-related protein 5 (SFRP5) binding proteins |
| WO2015095002A1 (en) | 2013-12-16 | 2015-06-25 | Texas Tech University System | Anti-ron monoclonal antibodies as a cytotoxic drug delivery system for targeted cancer therapy |
| PL235555B1 (pl) | 2014-06-24 | 2020-09-07 | Inst Biotechnologii I Antybiotykow | Wyizolowany i oczyszczony polipeptyd hemaglutyniny (HA ) wirusa grypy H5N1, kompozycja zawierająca polipeptyd i jej zastosowanie, przeciwciało wiążące się specyficznie z polipeptydem oraz sposób otrzymywania tego polipeptydu |
| MX378904B (es) | 2014-07-10 | 2025-03-10 | Janssen Vaccines & Prevention Bv | Vacunas para virus influenza y usos de las mismas. |
| SG11201610456UA (en) | 2014-07-10 | 2017-01-27 | Janssen Vaccines & Prevention Bv | Influenza virus vaccines and uses thereof |
| CN120137055A (zh) | 2014-07-17 | 2025-06-13 | 恺兴生命科技(上海)有限公司 | 靶向cld18a2的t淋巴细胞及其制备方法和应用 |
| TWI588260B (zh) | 2014-09-04 | 2017-06-21 | 國立清華大學 | 重組神經胺酸酶蛋白及其應用 |
| CA2974699A1 (en) | 2015-01-23 | 2016-07-28 | Icahn School Of Medicine At Mount Sinai | Influenza virus vaccination regimens |
| AU2016270474A1 (en) | 2015-06-04 | 2018-01-04 | University Of Southern California | Lym-1 and Lym-2 targeted CAR cell immunotherapy |
| WO2016205347A1 (en) | 2015-06-16 | 2016-12-22 | Icahn School Of Medicine At Mount Sinai | Influenza virus vaccines and uses thereof |
| CN108025092A (zh) | 2015-07-16 | 2018-05-11 | 塞勒兰特治疗公司 | 经半胱氨酸取代的免疫球蛋白 |
| CA2994516A1 (en) | 2015-08-03 | 2017-02-09 | Novartis Ag | Methods of treating fgf21-associated disorders |
| US10709565B2 (en) | 2015-08-27 | 2020-07-14 | Zimmer, Inc. | Directional locking reverse shoulder prostheses and systems |
| US20200237898A1 (en) | 2015-09-21 | 2020-07-30 | Oregon Health & Science University | Vaccines intelligently produced by epitope recombination (viper) for influenza |
| US10063211B2 (en) | 2016-02-03 | 2018-08-28 | Qualcomm Incorporated | Compact bypass and decoupling structure for millimeter-wave circuits |
| WO2017148889A1 (en) | 2016-03-01 | 2017-09-08 | Janssen Vaccines & Prevention B.V. | Human neutralizing antibodies binding to influenza b neuraminidase |
| WO2017210445A1 (en) | 2016-06-03 | 2017-12-07 | Icahn School Of Medicine At Mount Sinai | Influenza virus vaccination regimens |
| EP3255056A1 (en) | 2016-06-06 | 2017-12-13 | Commissariat À L'Énergie Atomique Et Aux Énergies Alternatives | Method for producing self-assemblying paramyxoviral nucleocapsid-like particles and their uses |
| BR112018075032A2 (pt) | 2016-06-15 | 2019-03-26 | Icahn School Of Medicine At Mount Sinai | proteínas de hemaglutinina do vírus influenza e seus uso |
| AU2017299581B2 (en) | 2016-07-20 | 2024-05-23 | EyePoint Pharmaceuticals, Inc. | Humanized monoclonal antibodies that target ve-ptp (hptp-β) |
| US20180128545A1 (en) | 2016-11-08 | 2018-05-10 | Berry Metal Company | Modular furnace cooling wall |
| AU2018219864B2 (en) | 2017-02-10 | 2025-02-27 | Mayo Foundation For Medical Education And Research | Trailshort antibody and methods of use |
| US11254733B2 (en) | 2017-04-07 | 2022-02-22 | Icahn School Of Medicine At Mount Sinai | Anti-influenza B virus neuraminidase antibodies and uses thereof |
| WO2019032463A1 (en) | 2017-08-07 | 2019-02-14 | Icahn School Of Medicine At Mount Sinai | IMMUNOGENIC COMPOSITIONS COMPRISING INFLUENZA VIRUS AND AS01 CHIMERIC POLYPEPTIDES OF HEMAGGLUTININ AND USES THEREOF |
| US12364746B2 (en) | 2018-06-21 | 2025-07-22 | Icahn School Of Medicine At Mount Sinai | Mosaic influenza virus hemagglutinin polypeptides and uses thereof |
| EP3959216A4 (en) | 2019-04-24 | 2023-01-11 | Icahn School of Medicine at Mount Sinai | ANTI-INFLUENZA B VIRUS NEURAMINIDASE ANTIBODIES AND USES THEREOF |
| WO2020264141A1 (en) | 2019-06-26 | 2020-12-30 | Icahn School Of Medicine At Mount Sinai | Influenza virus neuraminidase and uses thereof |
| CA3158412A1 (en) | 2019-10-22 | 2021-04-29 | Icahn School Of Medicine At Mount Sinai | Recombinant neuraminidase and uses thereof |
| JP2023511444A (ja) | 2020-01-24 | 2023-03-17 | ウィスコンシン アルムニ リサーチ ファンデイション | 安定化されたｎａを有する組換えインフルエンザウイルス |
| WO2023167868A2 (en) | 2022-03-01 | 2023-09-07 | Icahn School Of Medicine At Mount Sinai | Immunogenic compositions comprising a recombinant neuraminidase and cpg oligonucleotide adjuvant, and uses thereof |
-
2017
- 2017-06-14 BR BR112018075032-8A patent/BR112018075032A2/pt not_active IP Right Cessation
- 2017-06-14 MX MX2018015755A patent/MX2018015755A/es unknown
- 2017-06-14 CN CN201780049845.1A patent/CN109641041A/zh active Pending
- 2017-06-14 EP EP17813990.3A patent/EP3471767A4/en active Pending
- 2017-06-14 CA CA3023143A patent/CA3023143A1/en active Pending
- 2017-06-14 US US16/305,845 patent/US11266734B2/en active Active
- 2017-06-14 JP JP2018565670A patent/JP7237344B2/ja active Active
- 2017-06-14 WO PCT/US2017/037384 patent/WO2017218624A1/en not_active Ceased
-
2022
- 2022-01-24 US US17/583,088 patent/US11865173B2/en active Active
- 2022-08-24 JP JP2022133019A patent/JP2022176993A/ja active Pending
-
2023
- 2023-11-17 US US18/512,751 patent/US12233123B2/en active Active
-
2024
- 2024-12-16 US US18/983,218 patent/US20250121049A1/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104185476A (zh) * | 2011-09-20 | 2014-12-03 | 西奈山医学院 | 流感病毒疫苗及其应用 |
| CN105263516A (zh) * | 2012-12-18 | 2016-01-20 | 西奈山伊坎医学院 | 流感病毒疫苗及其用途 |
Non-Patent Citations (4)
| Title |
|---|
| KRAMMER ET AL: ""Chimeric Hemagglutinin Influenza Virus Vaccine Constructs Elicit Broadly Protective Stalk-Specific Antibodies"", 《JOURNAL OF VIROLOGY》 * |
| NI ET AL: ""Structural basis for the divergent evolution of influenza B virus hemagglutinin"", 《VIROLOGY》 * |
| OHKURA ET AL: ""Epitope Mapping Of Neutralizing Monoclonal Antibody In Avian Influenza A H5N1 Virus Hemagglutinin"", 《BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS》 * |
| WANG ET AL: ""Crystal Structure of Unliganded Influenza B Virus Hemagglutinin"", 《JOURNAL OF VIROLOGY》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2017218624A8 (en) | 2018-04-12 |
| EP3471767A1 (en) | 2019-04-24 |
| US20240335524A1 (en) | 2024-10-10 |
| US11865173B2 (en) | 2024-01-09 |
| CA3023143A1 (en) | 2017-12-21 |
| US20250121049A1 (en) | 2025-04-17 |
| JP7237344B2 (ja) | 2023-03-13 |
| US20190314485A1 (en) | 2019-10-17 |
| EP3471767A4 (en) | 2020-01-15 |
| JP2022176993A (ja) | 2022-11-30 |
| JP2019521674A (ja) | 2019-08-08 |
| US11266734B2 (en) | 2022-03-08 |
| US20220257749A1 (en) | 2022-08-18 |
| MX2018015755A (es) | 2019-08-29 |
| BR112018075032A2 (pt) | 2019-03-26 |
| US12233123B2 (en) | 2025-02-25 |
| WO2017218624A1 (en) | 2017-12-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12233123B2 (en) | Influenza virus hemagglutinin proteins and uses thereof | |
| US9849172B2 (en) | Influenza virus vaccines and uses thereof | |
| US12364746B2 (en) | Mosaic influenza virus hemagglutinin polypeptides and uses thereof | |
| US10179806B2 (en) | Influenza virus vaccines and uses thereof | |
| US10131695B2 (en) | Influenza virus vaccines and uses thereof | |
| US9701723B2 (en) | Vaccines for use in the prophylaxis and treatment of influenza virus disease | |
| WO2020264141A1 (en) | Influenza virus neuraminidase and uses thereof | |
| CA2974699A1 (en) | Influenza virus vaccination regimens | |
| CN108130345A (zh) | 基于副流感病毒5的疫苗 | |
| JP2022553342A (ja) | 組換えノイラミニダーゼ及びその使用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190416 |
|
| RJ01 | Rejection of invention patent application after publication |